FRANKLIN, Mass., March 10, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the ROTH 23rd Annual Growth Stock Conference.
Dr. Mooney will make a corporate presentation to prospective corporate partners and investors on Tuesday, March 15th at 3:30PM PST. The Company's presentation will be delivered at the Ritz Carlton Laguna Niguel in Dana Point, California.
About Echo TherapeuticsEcho is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals. For More Information:Patrick T. Mooney, M.D.
Media: Richard SternChairman and Chief Executive Officer
Stern & Co.(508)530-0329